NO20060808L - Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom - Google Patents

Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom

Info

Publication number
NO20060808L
NO20060808L NO20060808A NO20060808A NO20060808L NO 20060808 L NO20060808 L NO 20060808L NO 20060808 A NO20060808 A NO 20060808A NO 20060808 A NO20060808 A NO 20060808A NO 20060808 L NO20060808 L NO 20060808L
Authority
NO
Norway
Prior art keywords
treatment
joint disease
pak
pak inhibitor
inhibitor
Prior art date
Application number
NO20060808A
Other languages
English (en)
Inventor
Thomas Leeuw
Ekkehard Leberer
Eckart Bartnik
Joerg Czech
Sebastian Barradeau
Andreas Klatt
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20060808L publication Critical patent/NO20060808L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Oppfinnelsen refererer til bruken av p21 -aktivert kinase (PAK) inhibitor for behandling av en leddsykdom, slik som osteoartritt eller reumatoid artritt, eller for behandling av en leddsmerte og bruken a PAK som et målprotein for oppdagelsen av PAK-inhibitor som et medikament for behandling av en leddsykdom
NO20060808A 2003-07-18 2006-02-20 Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom NO20060808L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03016303A EP1498133A1 (en) 2003-07-18 2003-07-18 Use of a pak inhibitor for the treatment of a joint disease
PCT/EP2004/007855 WO2005011721A2 (en) 2003-07-18 2004-07-15 Use of a pak inhibitor for the treatment of a joint disease

Publications (1)

Publication Number Publication Date
NO20060808L true NO20060808L (no) 2006-04-12

Family

ID=33462155

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060808A NO20060808L (no) 2003-07-18 2006-02-20 Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom

Country Status (14)

Country Link
EP (3) EP1498133A1 (no)
JP (1) JP4843487B2 (no)
KR (2) KR101238755B1 (no)
CN (1) CN1826130B (no)
AU (1) AU2004260590B2 (no)
BR (1) BRPI0412760A (no)
CA (1) CA2532742C (no)
HK (1) HK1096854A1 (no)
IL (3) IL173145A (no)
MX (1) MXPA06000637A (no)
NO (1) NO20060808L (no)
RU (1) RU2360696C2 (no)
WO (1) WO2005011721A2 (no)
ZA (1) ZA200510377B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US20070264678A1 (en) 2005-10-28 2007-11-15 Invitrogen Corporation Kinase and ubiquination assays
US20090022712A1 (en) * 2006-01-24 2009-01-22 University Of Virginia Patent Foundation Compositions and Methods for Inhibiting Leukocyte Function
KR100835795B1 (ko) * 2006-11-17 2008-06-09 김응국 키나아제 팩2의 활성을 저해하는 펩타이드
EP2322220B1 (en) 2008-08-01 2014-01-01 Axis, Inc. Therapeutic agent or preventive agent for osteoarthritis
GB0814570D0 (en) 2008-08-08 2008-09-17 Diagnostics For The Real World Isolation of nucleic acid
WO2010017478A2 (en) * 2008-08-08 2010-02-11 The Board Of Trustees Of The University Of Illinois Pak1 agonists and methods of use
WO2010115841A1 (en) * 2009-04-01 2010-10-14 Galapagos Nv Methods and means for treatment of osteoarthritis
KR101684246B1 (ko) 2010-01-29 2016-12-08 가부시키가이샤 아크시스 변형성 관절증 치료제를 포함하는 주사제
CN102811737A (zh) 2010-01-29 2012-12-05 阿克西斯股份有限公司 骨关节炎治疗及预防药物组合物和上述组合物的制造方法
JP2012246222A (ja) 2010-01-29 2012-12-13 Axis Inc 変形性関節症治療剤または予防剤を製造するための使用
US20200190216A1 (en) * 2017-06-02 2020-06-18 Merck Patent Gmbh Mmp13 binding immunoglobulins
CN114042053B (zh) * 2021-10-25 2023-07-25 北京理工大学 siRNA输送载体及其制备方法和应用
WO2023097475A1 (zh) * 2021-11-30 2023-06-08 绍兴守仁医疗健康科技有限公司 人pak1蛋白的真核表达载体的构建方法、表达和纯化方法
CN114767864B (zh) * 2022-05-10 2023-05-12 天津医科大学总医院 Pak3抑制剂在治疗瑞芬太尼诱发的切口痛觉过敏中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE174600T1 (de) 1993-10-27 1999-01-15 Ribozyme Pharm Inc 2'-amido-und 2'-peptido-modifizierte oligonukleotide
US5518911A (en) * 1995-01-06 1996-05-21 Onyx Pharmaceuticals, Inc. Human PAK65
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
GB9602326D0 (en) 1996-02-06 1996-04-03 Cruachem Ltd Compounds
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
ES2177962T3 (es) 1996-03-25 2002-12-16 Lohmann Therapie Syst Lts Sistema de administracion transdermica de reducido espesor de aplicacion y elevada flexibilidad, y proceso de fabricacion del mismo.
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
WO1998037240A1 (en) 1997-02-24 1998-08-27 Tm Technologies, Inc. Anti-sense oligonucleotide pharmacological agents
US6383734B1 (en) * 1998-09-30 2002-05-07 Advanced Research And Technology Institute, Inc. Method to determine inhibition of PAK3 activation of Raf-1
AU3566200A (en) * 1999-04-01 2000-10-23 Astrazeneca Uk Limited Human signal transduction serine/threonine protein kinase

Also Published As

Publication number Publication date
IL173145A0 (en) 2006-06-11
KR101238755B1 (ko) 2013-03-07
RU2006105013A (ru) 2006-06-27
CA2532742C (en) 2013-07-09
EP2275116A1 (en) 2011-01-19
JP2007537134A (ja) 2007-12-20
CA2532742A1 (en) 2005-02-10
IL198727A (en) 2011-03-31
MXPA06000637A (es) 2006-08-23
KR20060052832A (ko) 2006-05-19
JP4843487B2 (ja) 2011-12-21
WO2005011721A3 (en) 2005-04-21
WO2005011721A2 (en) 2005-02-10
ZA200510377B (en) 2006-10-25
KR101299936B1 (ko) 2013-08-26
EP1498133A1 (en) 2005-01-19
HK1096854A1 (en) 2007-06-15
KR20120034250A (ko) 2012-04-10
AU2004260590A1 (en) 2005-02-10
IL204861A (en) 2011-09-27
CN1826130A (zh) 2006-08-30
EP1648486A2 (en) 2006-04-26
RU2360696C2 (ru) 2009-07-10
IL173145A (en) 2010-12-30
AU2004260590B2 (en) 2010-06-03
BRPI0412760A (pt) 2006-09-26
CN1826130B (zh) 2012-08-29

Similar Documents

Publication Publication Date Title
NO20060808L (no) Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
GT200900147A (es) Derivados de pirimidina y los métodos para su uso
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20092274L (no) Ansamycinformuleringer og fremgangsmater for anvendelse derav
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
TNSN06058A1 (en) Thienopyrazoles
SI1536827T1 (sl) Uporaba protein-kinaze n beta
DK1423384T3 (da) Pyridinderivater som Raf kinaseinhibitorer
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
NO20056046L (no) Oralt dispergerbar flerlags tablett
NO20081878L (no) Diacylindazolderivater som lipase- og fosfolipaseinhibitorer
CY1107294T1 (el) Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες
MX2022004937A (es) Inhibidores de las cinasas raf.
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20051838L (no) Nye triazol- og oksazolforbindelser som transformerende vekstfaktor (TGF) inhibitor.
NO20084749L (no) Organiske forbindelser og deres anvendelser
NO20014986L (no) 4,5-diaryl-3(2H)-furanonderivater som cyklooksygenase-2- inhibitorer
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
NO20082699L (no) Immunoglobuliner
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
BRPI0513051A (pt) combinação de inibidores de transcriptase reversa e de protease anti-hiv
ATE438618T1 (de) Inhibitoren von humanem adam-10
BR112021022380A2 (pt) Inibidores de jak

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application